Jarius, S.
Wilken, D.
Haas, J.
Ruprecht, K.
Komorowski, L.
Wildemann, B.
Funding for this research was provided by:
Universitätsklinikum Heidelberg
Article History
Received: 8 January 2021
Revised: 11 February 2021
Accepted: 13 February 2021
First Online: 26 March 2021
Compliance with ethical standards
:
: Sven Jarius and Jürgen Haas report no conflicts of interest. Diana Wilken and Lars Komorowski are employees of Euroimmun AG, Lübeck, Germany. Klemens Ruprecht received research support from Novartis, Merck Serono, German Ministry of Education and Research, European Union (821283-2), Stiftung Charité (BIH Clinical Fellow Program) and Arthur Arnstein Foundation; received speaker honoraria and travel grants from Bayer, Biogen Idec, Merck Serono, sanofi-aventis/Genzyme, Teva, Roche, Novartis, and Guthy Jackson Charitable Foundation, none of which are related to the present study. Brigitte Wildemann received grants from German Ministry of Education and Research, Deutsche Forschungsgemeinschaft, Dietmar Hopp Foundation, and Klaus Tschira Foundation, grants and personal fees from Merck Serono, Sanofi Genzyme, and Novartis pharmaceuticals, and personal fees from Bayer Healthcare, Biogen, Teva Pharma, none of which are related to the present study.